pioglitazone and Carotid Artery Diseases studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Carotid Artery Diseases: Pathological conditions involving the CAROTID ARTERIES, including the common, internal, and external carotid arteries. ATHEROSCLEROSIS and TRAUMA are relatively frequent causes of carotid artery pathology.

Research Excerpts

Excerpt	Relevance	Reference
"To determine whether changes in standard and novel risk factors during the Actos Now for Prevention of Diabetes trial explained the slower rate of carotid intima media thickness (CIMT) progression with pioglitazone treatment in persons with prediabetes."	9.17	Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. ( Banerji, M; Bray, GA; Buchanan, TA; Clement, SC; DeFronzo, RA; Henry, RR; Hodis, HN; Kitabchi, AE; Mack, WJ; Mudaliar, S; Musi, N; Ratner, RE; Reaven, PD; Saremi, A; Schwenke, DC; Stentz, FB; Tripathy, D, 2013)
"The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging."	9.15	Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011)
"Pioglitazone added to successful statin therapy may be beneficial for coronary artery disease (CAD) patients without diabetes mellitus."	9.13	Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease. ( Horibata, Y; Matsuzawa, Y; Nozaki, T; Ogawa, H; Sugamura, K; Sugiyama, S, 2008)
"To determine whether changes in standard and novel risk factors during the Actos Now for Prevention of Diabetes trial explained the slower rate of carotid intima media thickness (CIMT) progression with pioglitazone treatment in persons with prediabetes."	5.17	Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. ( Banerji, M; Bray, GA; Buchanan, TA; Clement, SC; DeFronzo, RA; Henry, RR; Hodis, HN; Kitabchi, AE; Mack, WJ; Mudaliar, S; Musi, N; Ratner, RE; Reaven, PD; Saremi, A; Schwenke, DC; Stentz, FB; Tripathy, D, 2013)
"The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging."	5.15	Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011)
"Pioglitazone added to successful statin therapy may be beneficial for coronary artery disease (CAD) patients without diabetes mellitus."	5.13	Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease. ( Horibata, Y; Matsuzawa, Y; Nozaki, T; Ogawa, H; Sugamura, K; Sugiyama, S, 2008)
"To compare the effects of rosiglitazone and pioglitazone on inflammatory mediators associated with atherosclerosis and CVD, surrogate cardiovascular endpoints, and hard cardiovascular outcomes in patients with type 2 diabetes."	4.85	Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes. ( Fisher, M, 2009)
"Pioglitazone treatment led to improvement in levels of multiple cardiovascular risk markers, including high-sensitivity C-reactive protein, apolipoprotein B, apolipoprotein A1, high-density lipoprotein (HDL) cholesterol, triglyceride, insulin, and free fatty acid."	2.73	Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. ( Chen, Z; D'Agostino, R; Davidson, M; Feinstein, S; Haffner, S; Kondos, GT; Mazzone, T; Meyer, PM; Perez, A, 2008)
"The pioglitazone-treated carriers of the D allele showed an attenuation of MaxIMT as compared with the diet-treated carriers."	1.36	Genetic risk factors and the anti-atherosclerotic effect of pioglitazone on carotid atherosclerosis of subjects with type 2 diabetes--a retrospective study. ( Kaneto, H; Katakami, N; Kawamori, R; Matsuhisa, M; Osonoi, T; Saitou, M; Yamasaki, Y, 2010)

Research

Studies (15)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Change From Baseline in Fasting Plasma Glucose of 2.4 Years

Change From Baseline in Matsuda Index of Insulin Sensitivity (There Are no Minimum/Maximum Values)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (26.67)	29.6817
2010's	11 (73.33)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Liu, J	1
Wang, LN	1
Zhao, D	1
Zhu, Z	1
Li, D	1
Xu, R	1
Wang, T	1
Liu, K	1
Sugamura, K	1
Sugiyama, S	1
Matsuzawa, Y	1
Nozaki, T	1
Horibata, Y	1
Ogawa, H	1
Fisher, M	1
Saitou, M	1
Osonoi, T	1
Kawamori, R	2
Katakami, N	2
Kaneto, H	1
Matsuhisa, M	1
Yamasaki, Y	2
Davidson, MH	1
Beam, CA	1
Haffner, S	2
Perez, A	2
D'Agostino, R	2
Mazzone, T	2
Furukado, S	1
Kitagawa, K	1
Nagatsuka, K	1
Kashiwagi, A	1
Daida, H	1
Kaku, K	1
Chang, K	1
Francis, SA	1
Aikawa, E	1
Figueiredo, JL	1
Kohler, RH	1
McCarthy, JR	1
Weissleder, R	1
Plutzky, J	1
Jaffer, FA	1
Joya-Galeana, J	1
Fernandez, M	1
Cervera, A	1
Reyna, S	1
Ghosh, S	1
Triplitt, C	1
Musi, N	2
DeFronzo, RA	2
Cersosimo, E	1
Tawakol, A	1
Finn, AV	1
Mizoguchi, M	1
Tahara, N	1
Tahara, A	1
Nitta, Y	1
Kodama, N	1
Oba, T	1
Mawatari, K	1
Yasukawa, H	1
Kaida, H	1
Ishibashi, M	1
Hayabuchi, N	1
Harada, H	1
Ikeda, H	1
Yamagishi, S	1
Imaizumi, T	1
Marwick, TH	1
Narula, J	1
Saremi, A	1
Schwenke, DC	1
Buchanan, TA	2
Hodis, HN	2
Mack, WJ	1
Banerji, M	1
Bray, GA	1
Clement, SC	1
Henry, RR	1
Kitabchi, AE	1
Mudaliar, S	1
Ratner, RE	1
Stentz, FB	1
Tripathy, D	1
Reaven, PD	1
Xiang, AH	1
Kawakubo, M	1
Peters, RK	1
Kjos, SL	1
Marroquin, A	1
Goico, J	1
Ochoa, C	1
Liu, CR	1
Liu, CH	1
Davidson, M	1
Meyer, PM	1
Feinstein, S	1
Kondos, GT	1
Chen, Z	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT[NCT00722631]		70 participants (Actual)	Interventional	2007-05-31	Completed
Actos Now for Prevention of Diabetes (ACT NOW)[NCT00220961]	Phase 3	602 participants (Actual)	Interventional	2004-01-31	Completed
A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Atherosclerotic Disease as Measured by Carotid Intima-Media Thickn[NCT00225264]	Phase 3	458 participants (Actual)	Interventional	2003-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	mg/dl (Mean)
Placebo	-4.0
Pioglitazone	-10.7

Insulin sensitivity The Matsuda index was calculated as 10,000/square root of (pre-meal glucose x pre-meal insulin x mean 120 min post-meal glucose x mean 120 min post-meal insulin), with higher numbers indicating better the insulin sensitivity. (NCT00220961)
Timeframe: Baseline versus 2.4 years

Change From Baseline in Plasma Insulin Concentration During Oral Glucose Tolerance Test

Change in Atherosclerosis

Prevention of Type 2 Diabetes

Intervention	matsuda index (Mean)
Placebo	0.7
Pioglitazone	3.6

Intervention	nmol (Mean)
Placebo	35
Pioglitazone	25

Intervention	percentage of intima (Mean)
Placebo	1.7
Pioglitazone	3.2

Percentage of Participants with Type 2 Diabetes at 2.4 years Post-randomization (NCT00220961)
Timeframe: 2.4 years

Article	Year
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack. The Cochrane database of systematic reviews, 2017, 12-02, Volume: 12 Topics: Cardiovascular Diseases; Carotid Artery Diseases; Humans; Hypoglycemic Agents; Insulin Resistance; I	2017
Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes. International journal of clinical practice, 2009, Volume: 63, Issue:9 Topics: Atherosclerosis; Biomarkers; Blood Glucose; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diab	2009

Article	Year
Pioglitazone Suppresses CXCR7 Expression To Inhibit Human Macrophage Chemotaxis through Peroxisome Proliferator-Activated Receptor γ. Biochemistry, 2015, Nov-17, Volume: 54, Issue:45 Topics: Benzamides; Carotid Artery Diseases; Cell Differentiation; Cells, Cultured; Chemotaxis; Combined Mod	2015
Genetic risk factors and the anti-atherosclerotic effect of pioglitazone on carotid atherosclerosis of subjects with type 2 diabetes--a retrospective study. Journal of atherosclerosis and thrombosis, 2010, Apr-30, Volume: 17, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Female; Humans;	2010
Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging. Arteriosclerosis, thrombosis, and vascular biology, 2010, Volume: 30, Issue:10 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipoproteins E; Carotid Artery Diseases; Choles	2010
Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride. JACC. Cardiovascular imaging, 2011, Volume: 4, Issue:10 Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Aortography; Atherosclerosis; Carotid Art	2011
Imaging of pharmacologic intervention decoding therapeutic mechanism or defining effectiveness? JACC. Cardiovascular imaging, 2011, Volume: 4, Issue:10 Topics: Anti-Inflammatory Agents; Aortic Diseases; Aortography; Carotid Artery Diseases; Diabetes Mellitus,	2011

pioglitazone and Carotid Artery Diseases